Endo Oxymorphone ER Protocol Approved
This article was originally published in The Pink Sheet Daily
Executive Summary
Endo expects to submit a complete response to FDA's "approvable" letter for its extended-release oxymorphone "in early 2006.
You may also be interested in...
Endo Submits "Complete Response" For Oxymorphone ER
Filing includes data from two additional clinical trials in opioid-naive and opioid-experienced patients, company says.
Endo Submits "Complete Response" For Oxymorphone ER
Filing includes data from two additional clinical trials in opioid-naive and opioid-experienced patients, company says.
Endo’s Oxymorphone Solid Tablet Could Be Unscathed By Palladone Withdrawal
Purdue’s withdrawal of its opiate Palladone may not impact Endo’s pending oxymorphone product because of formulation differences, the company says. Endo hopes to avoid marketing restrictions for oxymorphone based on a broad clinical development program.